Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

NCT06304883 is registered in ClinicalTrials.gov with Alzheon Inc. as lead sponsor.

NCT NCT06304883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06304883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Lead sponsor
Alzheon Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 2, 2024
Completion date
March 11, 2026
Enrollment
163 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

early alzheimer's disease